Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,accountsPayable,changeToLiabilities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,totalCashflowsFromInvestingActivities,capitalExpenditures,changeToInventory,WC,language,region,quoteType,triggerable,quoteSourceName,currency,esgPopulated,tradeable,exchangeDataDelayedBy,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingPE,epsTrailingTwelveMonths,epsForward,epsCurrentYear,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,exchange,marketState,market,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,IRWD,110192000,161967008,,,40358000,,39926000,27652000,73361000,45709000,45709000,,-7626000,,,,432000,88845000,43136000,15484000,-5351000,,39926000,39926000,1536160000,489152000,110192000,6875000,599344000,162000,1735000,-1426130000,9609000,36318000,438469000,23603000,24780000,538246000,87152000,436078000,842000,-7942000.0,2211000.0,-2582000.0,2211000.0,75905000.0,73694000.0,410000.0,35037000.0,8845000.0,,,,514643000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,4.6400003,0.53765935,8.63 - 14.27,-1.0,-0.070077084,8.63,14.27,1620304200,1635937140,1636372800,14.926885,0.889,1.18,1.27,1.2977104,13.04 - 13.4,13.1,0.0,0.0,30,30,finmb_31498,NasdaqGS,"Ironwood Pharmaceuticals, Inc.",USD,1892887,1398014,10.448819,0.68,13.161715,0.108285904,0.00822734,11.698768,1.5712328,0.13430755,2149302272,11.245764,19.514706,15,America/New_York,EDT,-14400000,2,NMS,PRE,us_market,"Ironwood Pharmaceuticals, Inc.",13.27,1630526403,0.17000008,13.1,13.4,13.04,1945860,1.33,,,14.27,8.63,13.16,11.7,1.89M,1.4M,161.97M,,143.12M,1.36%,108.58%,18.64M,11.04,21.74%,11.51%,18.31M,,,,,,0.00%,,,1194:1000,"Apr 01, 2019","Dec 30, 2020","Mar 30, 2021",35.83%,48.04%,23.85%,739.00%,398.42M,2.49,11.10%,298.32M,193.5M,142.76M,0.89,"1,093.60%",438.47M,2.71,459.08M,416.62,22.80,0.68,198.93M,130.61M,Value,02110,Healthcare,232,5,2,"Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.",Boston,617 621 7722,MA,6,1609372800,1622505600,1,United States,http://www.ironwoodpharma.com,86400,3,100 Summer Street,617 494 0480,Drug Manufacturers—Specialty & Generic,Suite 2300
t-1,IRWD,62640000,161967008,,,44500000,,43204000,33382000,99516000,66134000,66134000,,-7521000,,,,1296000,116680000,50546000,17164000,-21634000,,43204000,43204000,1528535000,496598000,62640000,12110000,559238000,161000,1735000,-1466056000,13851000,37894000,362564000,32173000,25505000,495839000,122351000,430256000,661000,15000.0,3524000.0,1870000.0,3524000.0,55009000.0,51513000.0,-779000.0,-9305000.0,16508000.0,-28000.0,-28000.0,,463666000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,4.6400003,0.53765935,8.63 - 14.27,-1.0,-0.070077084,8.63,14.27,1620304200,1635937140,1636372800,14.926885,0.889,1.18,1.27,1.2977104,13.04 - 13.4,13.1,0.0,0.0,30,30,finmb_31498,NasdaqGS,"Ironwood Pharmaceuticals, Inc.",USD,1892887,1398014,10.448819,0.68,13.161715,0.108285904,0.00822734,11.698768,1.5712328,0.13430755,2149302272,11.245764,19.514706,15,America/New_York,EDT,-14400000,2,NMS,PRE,us_market,"Ironwood Pharmaceuticals, Inc.",13.27,1630526403,0.17000008,13.1,13.4,13.04,1945860,1.33,,,14.27,8.63,13.16,11.7,1.89M,1.4M,161.97M,,143.12M,1.36%,108.58%,18.64M,11.04,21.74%,11.51%,18.31M,,,,,,0.00%,,,1194:1000,"Apr 01, 2019","Dec 30, 2020","Mar 30, 2021",35.83%,48.04%,23.85%,739.00%,398.42M,2.49,11.10%,298.32M,193.5M,142.76M,0.89,"1,093.60%",438.47M,2.71,459.08M,416.62,22.80,0.68,198.93M,130.61M,Value,02110,Healthcare,232,5,2,"Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.",Boston,617 621 7722,MA,6,1609372800,1622505600,1,United States,http://www.ironwoodpharma.com,86400,3,100 Summer Street,617 494 0480,Drug Manufacturers—Specialty & Generic,Suite 2300
t-2,IRWD,5904000,161967008,,,35812000,,34423000,34928000,81776000,46848000,46848000,,-7419000,,,,1389000,103468000,56620000,21692000,-11036000,,34423000,34423000,1515004000,486420000,5904000,4064000,492324000,160000,1735000,-1509260000,8213000,32815000,307555000,32901000,26192000,433317000,113250000,424539000,1972000,5448000.0,670000.0,4025000.0,670000.0,54302000.0,53632000.0,1821000.0,-8073000.0,15988000.0,-28000.0,-28000.0,,400416000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,4.6400003,0.53765935,8.63 - 14.27,-1.0,-0.070077084,8.63,14.27,1620304200,1635937140,1636372800,14.926885,0.889,1.18,1.27,1.2977104,13.04 - 13.4,13.1,0.0,0.0,30,30,finmb_31498,NasdaqGS,"Ironwood Pharmaceuticals, Inc.",USD,1892887,1398014,10.448819,0.68,13.161715,0.108285904,0.00822734,11.698768,1.5712328,0.13430755,2149302272,11.245764,19.514706,15,America/New_York,EDT,-14400000,2,NMS,PRE,us_market,"Ironwood Pharmaceuticals, Inc.",13.27,1630526403,0.17000008,13.1,13.4,13.04,1945860,1.33,,,14.27,8.63,13.16,11.7,1.89M,1.4M,161.97M,,143.12M,1.36%,108.58%,18.64M,11.04,21.74%,11.51%,18.31M,,,,,,0.00%,,,1194:1000,"Apr 01, 2019","Dec 30, 2020","Mar 30, 2021",35.83%,48.04%,23.85%,739.00%,398.42M,2.49,11.10%,298.32M,193.5M,142.76M,0.89,"1,093.60%",438.47M,2.71,459.08M,416.62,22.80,0.68,198.93M,130.61M,Value,02110,Healthcare,232,5,2,"Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.",Boston,617 621 7722,MA,6,1609372800,1622505600,1,United States,http://www.ironwoodpharma.com,86400,3,100 Summer Street,617 494 0480,Drug Manufacturers—Specialty & Generic,Suite 2300
t-3,IRWD,-36852000,161967008,,,25204000,,25204000,34643000,67356000,32713000,32713000,,-7318000,,,,0,89432000,56719000,22076000,-7509000,,25204000,25204000,1506671000,480390000,-36852000,2626000,443538000,160000,1250000,-1543683000,13560000,40917000,253252000,26695000,28346000,374275000,105379000,418924000,2104000,-2093000.0,2397000.0,-3318000.0,2397000.0,22109000.0,20088000.0,640000.0,-14472000.0,13479000.0,-376000.0,-376000.0,648000.0,347580000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,4.6400003,0.53765935,8.63 - 14.27,-1.0,-0.070077084,8.63,14.27,1620304200,1635937140,1636372800,14.926885,0.889,1.18,1.27,1.2977104,13.04 - 13.4,13.1,0.0,0.0,30,30,finmb_31498,NasdaqGS,"Ironwood Pharmaceuticals, Inc.",USD,1892887,1398014,10.448819,0.68,13.161715,0.108285904,0.00822734,11.698768,1.5712328,0.13430755,2149302272,11.245764,19.514706,15,America/New_York,EDT,-14400000,2,NMS,PRE,us_market,"Ironwood Pharmaceuticals, Inc.",13.27,1630526403,0.17000008,13.1,13.4,13.04,1945860,1.33,,,14.27,8.63,13.16,11.7,1.89M,1.4M,161.97M,,143.12M,1.36%,108.58%,18.64M,11.04,21.74%,11.51%,18.31M,,,,,,0.00%,,,1194:1000,"Apr 01, 2019","Dec 30, 2020","Mar 30, 2021",35.83%,48.04%,23.85%,739.00%,398.42M,2.49,11.10%,298.32M,193.5M,142.76M,0.89,"1,093.60%",438.47M,2.71,459.08M,416.62,22.80,0.68,198.93M,130.61M,Value,02110,Healthcare,232,5,2,"Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.",Boston,617 621 7722,MA,6,1609372800,1622505600,1,United States,http://www.ironwoodpharma.com,86400,3,100 Summer Street,617 494 0480,Drug Manufacturers—Specialty & Generic,Suite 2300
